NCT04836429

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) With Pleural Disease or Malignant Pleural Mesothelioma (MPM) - Phase I Study

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I trial evaluates the side effects of intraoperative photodynamic therapy with porfimer sodium in enhancing the response to immunotherapy with an immune checkpoint inhibitor drug in patients with non-small cell lung cancer with pleural disease. Photodynamic therapy is a technique that that works by combining a photosensitizing agent (porfimer sodium in this trial) and an intense light source to kill tumor cells. Photodynamic therapy may decrease the patients' symptoms and improve their quality of life.

Conditions

• Lung Non-Small Cell Carcinoma
• Pleural Disorder

Interventions

Type	Name	Description
DRUG	Porfimer Sodium	Given IV
PROCEDURE	Video-Assisted Thoracic Surgery	Undergo VATS
DRUG	Photodynamic Therapy	Undergo photodynamic therapy
DEVICE	Intraoperative PDT	Subjects will receive one course of light therapy at the time of surgery

Timeline

• Start date: 2022-03-10
• Primary completion: 2024-02-03
• Completion: 2025-01-03
• First posted: 2021-04-08
• Last updated: 2026-02-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study